CClinicalTrials.gg
CompletedNCT07851961TENS-GAITUpdated Oct 5, 2026

Effect of Low-Frequency Low-Frequency Transcutaneous Electrical Nerve Stimulation of the Gluteus Medius on Gait and Balance

An observational study in Gait Analysis in Healthy Subjects, sponsored by Ankara University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Ankara University · Observational

Updated Oct 5, 2026Eligibility revisedPrimary outcomes revised+1 moreGo to Updates ↓
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
22
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the immediate effects of applying low-frequency Transcutaneous Electrical Nerve Stimulation (TENS) to the gluteus medius muscle on gait and balance in healthy young adults.

The gluteus medius is a major hip muscle that plays a crucial role in stabilizing the pelvis and maintaining postural balance during walking. Although TENS is widely used in clinical settings, its immediate impact on multi-planar walking kinematics and stability when applied specifically to this muscle is not fully understood.

In this study, healthy young adult participants will receive a single 20-minute session of low-frequency TENS applied bilaterally to their gluteus medius muscles. Researchers will evaluate the participants' static and dynamic balance performance, as well as their three-dimensional walking patterns, immediately before and after the electrical stimulation to observe any acute changes in their physical performance and stabilization strategies.

02

Conditions studied

  • Gait Analysis in Healthy Subjects

Keywords

  • TENS
  • Gluteus medius
  • Gait Analysis
  • postural balance
03

In context

Lead sponsor

Ankara University is the lead sponsor of 312 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population consists of healthy young adults, primarily recruited from the local university and surrounding community.

Inclusion criteria

  • Individuals aged 18-45 years with no history of orthopedic surgeries
  • Neurological disorders, or chronic lower limb pain within the last six months

Exclusion criteria

Exclusion Criteria:

  • Current lower extremity pain
  • Previous lower limb surgery
  • Known balance impairments or any contraindications to TENS (such as cardiac pacemakers or skin hypersensitivities)
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
22 participants (actual)
Patient registry
No

Groups and cohorts

  • Low-frequency TENS Group
06

What researchers measure

Primary outcomes

  1. Change in Static and Dynamic Balance

    Balance performance is assessed using the BOBO Pro 2 system. The system evaluates static and dynamic balance parameters, providing a balance score expressed as a percentage (%). Higher scores indicate better postural stability and balance performance.

    Time frame: Baseline before intervention and immediately after the 20-minute TENS intervention.

  2. Change in Three-Dimensional Gait Kinematics

    Multi-planar gait kinematics, focusing specifically on frontal, sagittal, and transverse plane parameters (such as hip adduction-abduction range of motion and pelvic obliquity), are captured and analyzed using the VICON motion capture system. Values are recorded in degrees (°).

    Time frame: Baseline before intervention and immediately following the 20-minute TENS.

07

Study locations

1 site
  • Faculty of Health Sciences, Ankara University
    Ankara, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared publicly. Aggregate data will be available in the published manuscript.

No publications or documents are linked to this record.

09

Updates

2 registry updates since Sep 25, 2026
Also revised
eligibility and primary outcomes
Registered
First appeared on the registry
Oct 1, 2026
Show all 2 updates
  1. Oct 5, 2026
    Eligibility Criteria revised
    Primary outcomes Revised (3 changes)
    + 2 other changes: identifiers and description
  2. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07851961
Lead sponsor
Ankara University
Responsible party
Naime Uluğ (Assistant professor, Ankara University) — Principal investigator
First posted
Oct 1, 2026
Start date
Jan 15, 2026
Primary completion
Feb 25, 2026
Completion
May 15, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion